Arbutus Biopharma (ABUS) Current Deferred Revenue (2016 - 2025)
Historic Current Deferred Revenue for Arbutus Biopharma (ABUS) over the last 13 years, with Q1 2025 value amounting to $6.8 million.
- Arbutus Biopharma's Current Deferred Revenue fell 4146.53% to $6.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $6.8 million, marking a year-over-year decrease of 4146.53%. This contributed to the annual value of $7.6 million for FY2024, which is 3579.0% down from last year.
- Latest data reveals that Arbutus Biopharma reported Current Deferred Revenue of $6.8 million as of Q1 2025, which was down 4146.53% from $7.6 million recorded in Q4 2024.
- Arbutus Biopharma's 5-year Current Deferred Revenue high stood at $23.3 million for Q1 2022, and its period low was $6.8 million during Q1 2025.
- Over the past 4 years, Arbutus Biopharma's median Current Deferred Revenue value was $12.1 million (recorded in 2023), while the average stood at $13.4 million.
- Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 969.78% in 2023, then crashed by 4146.53% in 2025.
- Over the past 4 years, Arbutus Biopharma's Current Deferred Revenue (Quarter) stood at $16.5 million in 2022, then fell by 28.35% to $11.8 million in 2023, then crashed by 35.79% to $7.6 million in 2024, then dropped by 10.73% to $6.8 million in 2025.
- Its last three reported values are $6.8 million in Q1 2025, $7.6 million for Q4 2024, and $10.9 million during Q3 2024.